Composition
active ingredient carbocisteine
Paediatric syrup: each 5 ml contains 100 mg.

excipients:
Paediatric syrup: methyl paraben, propylparaben, glycerin, sorbitol 70%,caramel colour, tutti frutti flavour,sodium hydroxide, purified water.
therapeutic indications:
carbocisteine ( active ingredient ) is a mucolytic agent for the therapy of respiratory tract disorders characterized by excessive viscous mucus including chronic obstructive Airways disease.
posology and method of administration
adults Including the elderly
- dosage is raised upon an initial daily dosage of 2250 mg carbocisteine in divided doses, Reducing to 1500 mg daily in divided doses when a satisfactory response is obtained e.g. 15 ml three times daily reducing to 10 ml three times a day.
children:
- The normal daily dosage is 20 mg/kg body weight in divided doses.
- It is recommended that this is achieved with Carbolase pediatric syrup.
- children 2-5 years: 2.5 -5 ml four times daily.
- children 5-12 years: 10 ml three times daily.
- pediatric syrup and adult syrup are for oral administration.
Contraindications:
pediatric syrup:
- Carbolase paediatric is contraindicated for use in children less than 2 years age.(Postmarketing reports of it’s side effects showed that the use of all mucolytic as carbocisteine May worsen the expected Respiratory manifestations and the side effects outweigh the benefits of its usage for children less than two years old).
- hypersensitivity to the active substance or to any of the excipients..
special warning and precautions for use
a patient with rare hereditary problems of fructose intolerance, glucose-galactose malabsorption should not take this medicine.
Interactions with other medicinal products and other forms of interaction
none stated
Effects on ability to drive and use machines
The medicinal product has no or negligible influence on the ability to drive and use machines
pregnancy and lactation
- Although tests in mammalian species have revealed no teratogenic effects, Carbolase is not recommended during the first trimester of pregnancy.
- use in lactation: effects not known.
Undesired effects
- immune system disorders: there have been reports of anaphylactic reactions in fixed drug eruption.
- Skin and subcutaneous tissue disorders: there have been reports of skin rashes and allergic skin eruption.
- Gastrointestinal disorders: there have been rare reports of gastrointestinal bleeding during treatment with Carbolase.
overdose
- gastric lavage may be beneficial, followed by observation.
- Gastrointestinal Is the most likely symptom of Carbolase overdose..
pharmacological reports
Pharmacodynamic properties
- carbocisteine (S-carboxymethyl L-cystine) has been shown in normal bronchitic animal models to fake the nature and amount of mucus glycoprotein which is secreted by the respiratory tract.
- An increase in the acid neutral glycoprotein ratio of the mucus and a transformation of serous cells to mucus cells is known to be the initial response to irritation and will normally be followed by hypersecretion.
- The administration of carbocisteine to animals exposed to irritants indicates that the glycoprotein that is secreted remains normal; administration after exposure indicates that return to normal is accelerated.
- Studies in humans have demonstrated that carbocisteine reduces goblet cell hyperplasia.
- Carbocisteine can therefore be admistreated to have a role in the management of disorders characterized by abnormal mucus.
pharmacokinetic properties
- Carbocisteine Is rapidly absorbed from the GI tract.
- Bioavailability being low ( less than 10% of the taken dose). TC max in blood and in mucous membrane 1.5 – 2 hours, therapeutic concentration is preserved in blood within 8 hours. It is longer of all detained in blood, liver and middle ear. High concentration of the drug is accumulated in bronchial secretions (17.5% of taken dose). It is metabolized in the liver (having the effect of “first passage” through the liver). It is excreted by kidneys (60-90% – unchanged, the rest – in the form of metabolites). T ½ is 2-3.5 hours. Full excretion occurs in 3 days.
Shelf life
- Carbolase syrup (pediatric and adults): 36 months.
- store at a temperature not exceeding 30 ℃.
- Manufactured by : AMRIYA , Egypt.
Product information
Product | Carbolase adult & pediatric syrup |
Available concentrations | 100 mg |
Company | AMRIYA |
Country | Egypt. |
Active Ingredients | Carbocisteine |
Anatomical main group | RESPIRATORY SYSTEM |
Therapeutic subgroup | COUGH AND COLD PREPARATIONS |
Pharmacological subgroup | EXPECTORANTS, EXCL. COMBINATIONS WITH COUGH SUPPRESSANTS |
Chemical subgroup | Mucolytics |
ATC code | R05CB03 |
Legal status | Prescription only |
Contact Pharmacily administrator: If you have any notes or feedback you need to reach us with, feel free contacting us any time via e-mail( Listen2article@gmail.com). Please contact us via email (listen2article@gmail.com) or via contact us form, if the information on this page is incorrect, or if you have other information to update this page.